Orchard Therapeutics plc Contracts & Agreements
24 Contracts & Agreements
- Business Finance (4 contracts)
- Business Operations (5)
- Human Resources (9)
- Intellectual Property (1)
- Real Estate (1)
- Uncategorized (4)
- Contingent Value Rights Agreement, dated as of December 15, 2023, by and among Kyowa Kirin Co., Ltd and Wilmington Savings Fund Society, FSB (Filed With SEC on January 24, 2024)
- Transaction Agreement, dated October 5, 2023, by and between Orchard Therapeutics plc and Kyowa Kirin Co., Ltd. (Form of CVR Agreement included as Annex D thereto) (Filed With SEC on October 5, 2023)
- Form of Irrevocable Undertaking, dated October 5, 2023 (Filed With SEC on October 5, 2023)
- Form of Warrant (Filed With SEC on March 6, 2023)
- Securities Purchase Agreement dated March 6, 2023, by and among Orchard Therapeutics plc and the Purchasers named therein (Filed With SEC on March 6, 2023)
- Sales Agreement, dated October 6, 2022 (Filed With SEC on October 6, 2022)
- Amended and Restated Employment Agreement, dated October 4, 2022, between the Company, Orchard Therapeutics North America and Frank Thomas (Filed With SEC on October 6, 2022)
- Lease Agreement, dated April 5, 2022, among 245 Hammersmith Road Nominee 1 Limited, 245 Hammersmith Road Nominee 2 Limited, 245 Hammersmith Road Limited Partnership, and Orchard... (Filed With SEC on August 4, 2022)
- Amendment to the Transitional Services Agreement, dated March 30, 2022, between the Company, Orchard Therapeutics North America and Frank Thomas (Filed With SEC on March 30, 2022)
- Transitional Services Agreement, dated November 3, 2021, between the Company, Orchard Therapeutics North America and Frank Thomas (Filed With SEC on November 4, 2021)
- Securities Purchase Agreement dated February 4, 2021, by and among Orchard Therapeutics plc and the Purchasers named therein (Filed With SEC on February 9, 2021)
- Manufacturing and Technology Development Master Agreement, by and between Orchard Therapeutics (Europe) Limited, a wholly-owned subsidiary of the registrant, and MolMed S.p.A.,... (Filed With SEC on August 6, 2020)
- 2019 Short-Term Incentive Plan (Filed With SEC on May 7, 2020)
- Amendment Nos. 5 and 6 to License and Development Agreement, by and between the registrant and Oxford BioMedica (UK) Limited, dated November 28, 2016 (Filed With SEC on May 7, 2020)
- Amendment to Senior Term Facilities Agreement by and between the registrant and MidCap Financial (Ireland) Limited, as agent, dated April 7, 2020 (Filed With SEC on May 7, 2020)
- Separation Agreement and Release, dated March 17, 2020, by and among the Company, Orchard Therapeutics North America and Mark Rothera (Filed With SEC on March 20, 2020)
- Settlement Agreement without Prejudice and Subject to Contract, dated March 17, 2020, by and among the Company, Orchard Therapeutics (Europe) Limited, Orchard Therapeutics North... (Filed With SEC on March 20, 2020)
- Variation to Contract of Employment, dated March 18, 2020, by and between Orchard Therapeutics (Europe) Limited and Hubert Gaspar, M.D., Ph.D (Filed With SEC on March 20, 2020)
- First Amendment to Employment Agreement, dated March 18, 2020, by and among the Company, Orchard Therapeutics North America and Frank Thomas (Filed With SEC on March 20, 2020)
- Description of the registrants securities (Filed With SEC on February 27, 2020)
- Forms of award agreements under the 2018 Share Option and Incentive Plan (Filed With SEC on February 27, 2020)
- Employment Agreement between the registrant, Orchard Therapeutics North America, and Mark Rothera, effective May 30, 2019 (Filed With SEC on February 27, 2020)
- Employment Agreement between the registrant, Orchard Therapeutics North America, and Frank Thomas, effective September 1, 2019 (Filed With SEC on February 27, 2020)
- Contract of Employment between Orchard Therapeutics (Europe) Limited and Hubert Gaspar, dated January 8, 2018, as amended effective May 24, 2019 (Filed With SEC on February 27, 2020)
